Blade, Yes, nice moves for KZIA and MGTA, and ONCT is also looking good.
Btw, are you still following HGEN? It looks interesting for a possible run-up ahead of their Phase 3 topline data in March. CYDY is their main competitor in the Covid 'cytokine storm' space, and the CYDY Phase 3 data announcement is now long overdue (trial ended mid-Jan). CYDY has shady management, and in addition to HGEN's own Phase 3 data, HGEN could get an added boost if the CYDY trial disappoints.
TA/charts are not generally as useful with bio stocks, but the HGEN chart looks like an impending breakout.
Also, just curious if you are still in TRIL? Thanks.
News 
Market Data 
Discover 
